Brokerages Set Atara Biotherapeutics Inc. (NASDAQ:ATRA) Price Target at $21.25
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) have received an average rating of “Hold” from the eight brokerages that are covering the company. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $21.25.
ATRA has been the subject of several recent analyst reports. Jefferies Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Finally, Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $23.00 to $16.00 in a report on Thursday, September 15th.
In other Atara Biotherapeutics news, insider Christopher Haqq sold 1,346 shares of Atara Biotherapeutics stock in a transaction on Monday, August 15th. The shares were sold at an average price of $22.32, for a total transaction of $30,042.72. Following the completion of the sale, the insider now owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 12,000 shares of Atara Biotherapeutics stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $20.87, for a total transaction of $250,440.00. Following the sale, the chief executive officer now directly owns 406,578 shares of the company’s stock, valued at approximately $8,485,282.86. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in ATRA. JPMorgan Chase & Co. raised its stake in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares in the last quarter. RTW Investments LLC raised its stake in Atara Biotherapeutics by 11.1% in the first quarter. RTW Investments LLC now owns 473,126 shares of the company’s stock worth $9,004,000 after buying an additional 47,274 shares in the last quarter. A.R.T. Advisors LLC raised its stake in Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock worth $1,216,000 after buying an additional 28,330 shares in the last quarter. Bridger Management LLC acquired a new stake in Atara Biotherapeutics during the first quarter worth approximately $14,072,000. Finally, Bank of New York Mellon Corp raised its stake in Atara Biotherapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 99,629 shares of the company’s stock worth $2,243,000 after buying an additional 17,195 shares in the last quarter. 75.50% of the stock is owned by hedge funds and other institutional investors.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 20.46 on Thursday. Atara Biotherapeutics has a 12 month low of $13.31 and a 12 month high of $40.80. The stock’s 50 day moving average price is $20.77 and its 200-day moving average price is $20.29. The firm’s market cap is $589.47 million.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. Equities research analysts anticipate that Atara Biotherapeutics will post ($2.85) earnings per share for the current fiscal year.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.